If your period changes like this, it could mean there's a health issue
For instance, peptides that upregulate c-KIT or SCF pathways sustain early germ cell divisions and commitment to meiosis
Healthcare professionals continue to monitor for any emerging safety signals, and patients are encouraged to report any unusual symptoms through the Yellow Card scheme
Semaglutide Phase 2 Trial: 59% NASH resolution at 0.4 mg/day Building upon the foundation established by the LEAN trial, researchers subsequently conducted a larger phase 2 trial evaluating semaglutides efficacy in NASH patients

P-01 Hereditary angioedema with normal C1-INH and PLG muta-tion treated with tranexamic acid: Beware of the risk of thrombosis Alexis Bocquet, David Launay, Isabelle Boccon-Gibod, Aurlie Du-Thanh, Delphiine Gobert, Sbastien Sanges, Laurence Bouillet Launay &Sanges University of Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000, INSERM, and the Department of Internal Medicine and Clinical Immunology, CHU Lille, National Reference Center for Angioedema (CREAK), Lille, France Allergy, Asthma & Clinical Immunology 2025, 21(Suppl 2) :P-01 Introduction: The anti-fibrinolytic, tranexamic acid (TA) can be proposed as a long term prophylaxis for hereditary angioedema (HAE), and seems to be specifically efficient for HAE with plasminogen gene mutation (HAE-PLG), a subset of HAE with normal C1-INH (HAE-nC1-INH)
Compared to placebo, the GLP-1 group showed significantly lower post-cessation weight gain in both men and women